Cannabigerol is considered a minor cannabinoid. The cannabigerolic acid (CBGA) acts as a precursor to the main cannabinoid lines. The ultraviolet light breaks down this acid into cannabinoids THCA or CBDA. Crossbreeding of plants and genome therapies is believed to yield higher amounts of CBG. Furthermore, higher yields can also be obtained by knowing the optimal time of extraction from budding plants in a flowering cycle.
CBG is known to give specific physiological benefits and looks like a promising compound within cannabis. CBG is believed to effectively treat glaucoma by reducing intraocular pressure. CBG also acts as an effective vasodilator and has neuroprotective effects. Animal studies have shown CBG to be effective in treating inflammatory bowel disease and Huntington’s disease. CBG can possibly fight cancer by halting growth of cancer cells. Besides, CBG can act as an effective anti-bacterial agent, appetite stimulant as well as treat conditions of muscle wasting like cachexia. Furthermore, CBG can potentially treat bladder dysfunction disorders.
As CBG is a non-psychotropic cannabis strain, it is further being researched in treating multiple maladies. Cannabigerols can also be considered as an analgesic, a treatment option for psoriasis as well as in treating depression.
